Presentation is loading. Please wait.

Presentation is loading. Please wait.

Metabolite profiling of DFMO-treated ApcMin mouse tumors.

Published byClare Mason Modified over 5 years ago

Similar presentations

Presentation on theme: "Metabolite profiling of DFMO-treated ApcMin mouse tumors."— Presentation transcript:

1 Metabolite profiling of DFMO-treated ApcMin mouse tumors.
Metabolite profiling of DFMO-treated ApcMin mouse tumors. ApcMin mice were given DFMO by intraperitoneal injection (40 mg/kg daily) or vehicle (saline) for 21 days and intestinal tumors were microdissected and collected (3 tumors/mouse, n = 4 mice/group). Metabolites were extracted from tumors for analysis by high-performance liquid chromatography, as described in Methods. Along with accumulation of DFMO itself and expected decreases in polyamines, DFMO-treated tissues showed altered expression of methionine cycle and nucleotide/nucleoside levels, similar to in vitro findings (Fig. 3). Notably, this included markedly reduced thymidine levels. *, P < 0.05 by unpaired t test, comparing tumors from untreated and DFMO-treated ApcMin mice. N.D., not detected. Mavee Witherspoon et al. Cancer Discovery 2013;3: ©2013 by American Association for Cancer Research

Download ppt "Metabolite profiling of DFMO-treated ApcMin mouse tumors."

Similar presentations

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Effects of senescent cells on activity.

Effects of senescent cells on activity.
Binding of 53BP1 on uncapped telomeres.

Binding of 53BP1 on uncapped telomeres.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
BV6 increases tumor burden in bone.

BV6 increases tumor burden in bone.
H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
HER2 mutants V777L, G309A, D769H formed tumors more rapidly than HER2 WT. A, a total of 0.5 × 106 cells of NIH3T3 expressing either HER2 WT or mutant were.

HER2 mutants V777L, G309A, D769H formed tumors more rapidly than HER2 WT. A, a total of 0.5 × 106 cells of NIH3T3 expressing either HER2 WT or mutant were.
Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.
Estrogen drives accumulation of myelomonocytic (M-MDSC) and granulocytic (G-MDSC) MDSCs and increases the immunosuppressive potential of G-MDSCs. Estrogen.

Estrogen drives accumulation of myelomonocytic (M-MDSC) and granulocytic (G-MDSC) MDSCs and increases the immunosuppressive potential of G-MDSCs. Estrogen.
Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.

Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.
Effect of MI-773 and/or cisplatin in a preclinical model of ACC

Effect of MI-773 and/or cisplatin in a preclinical model of ACC
Activity of MAC-321 (i. v. and p. o

Activity of MAC-321 (i. v. and p. o
Effect of MI-773 dosing on long-term efficacy.

Effect of MI-773 dosing on long-term efficacy.
In vivo growth inhibition elicited by afatinib and GSK2849330 in a CLU–NRG1-rearranged PDX mouse model. In vivo growth inhibition elicited by afatinib.

In vivo growth inhibition elicited by afatinib and GSK in a CLU–NRG1-rearranged PDX mouse model. In vivo growth inhibition elicited by afatinib.
Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.
ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.

ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.
Metformin and rapamycin decreased tumor weights in obese prediabetic mice. Metformin and rapamycin decreased tumor weights in obese prediabetic mice. A:

Metformin and rapamycin decreased tumor weights in obese prediabetic mice. Metformin and rapamycin decreased tumor weights in obese prediabetic mice. A:
A: Chemical structure of pterosin A

A: Chemical structure of pterosin A
Systemic treatment with AMPK activators decreases TRPA1 associated with membrane in DRG neurons of db/db mice. Systemic treatment with AMPK activators.

Systemic treatment with AMPK activators decreases TRPA1 associated with membrane in DRG neurons of db/db mice. Systemic treatment with AMPK activators.
Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Similar presentations

Ads by Google